1. Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
   Sun Tae Hwang et al, 2020, Molecules CrossRef
2. MET expression during prostate cancer progression
   Esther I. Verhoef et al, 2016, Oncotarget CrossRef
3. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation
   Won Kyung Kim et al, 2024, Nature Communications CrossRef
4. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
   David S. Hong et al, 2015, Oncotarget CrossRef
5. Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells
   TIANCHENG LIU et al, 2014, International Journal of Oncology CrossRef
6. MET inhibition enhances PARP inhibitor efficacy in castration‐resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways
   Sihai Zhou et al, 2021, Journal of Cellular and Molecular Medicine CrossRef
7. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
   Arndt Katzenwadel et al, 2015, Cancer Letters CrossRef
8. AR imposes different effects on ZFHX3 transcription depending on androgen status in prostate cancer cells
   Xing Fu et al, 2022, Journal of Cellular and Molecular Medicine CrossRef
9. Testosterone serum levels and prostate cancer prognosis: the double face of Janus
   Francesca Valcamonico et al, 2014, Future Oncology CrossRef
10. Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
    Theodoros Karantanos et al, 2015, European Urology CrossRef
11. Photoreactive Molecular Glue for Enhancing the Efficacy of DNA Aptamers by Temporary-to-Permanent Conjugation with Target Proteins
    Ai Kohata et al, 2021, Journal of the American Chemical Society CrossRef
12. Evodiamine as the Active Compound of Evodiae fructus to Inhibit Proliferation and Migration of Prostate Cancer through PI3K/AKT/NF-κB Signaling Pathway
    Yuhe Lei et al, 2022, Disease Markers CrossRef
13. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
    Raya Leibowitz-Amit et al, 2016, Journal of Translational Medicine CrossRef
14. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
    Yuanyuan Qiao et al, 2016, Neoplasia CrossRef
15. Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer
    Izhar Batth et al, 2016, Oncotarget CrossRef
16. Met in Urological Cancers
    Yasuyoshi Miyata et al, 2014, Cancers CrossRef
17. c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications
    Ralf Hass et al, 2017, Cell Communication and Signaling CrossRef
18. The andrologist's contribution to a better life for ageing men: part 1
    F. Comhaire et al, 2016, Andrologia CrossRef
19. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy
    Mikolaj J. Filon et al, 2022, The Prostate CrossRef
20. Prolonged androgen deprivation leads to overexpression of calpain 2: Implications for prostate cancer progression
    TIANCHENG LIU et al, 2014, International Journal of Oncology CrossRef